FTSE MIB
33.825,45 -56,05 (-0,17%) Dow Jones
37.775,38 +22,07 (+0,06%) Nasdaq
15.601,50 -81,87 (-0,52%) Nikkei 225
37.068,35 -1.011,35 (-2,66%) Petrolio
82,30 -0,43 (-0,52%) Bitcoin EUR
60.992,96 +2.230,09 (+3,80%)
Lisata Therapeutics, Inc. (0HS8.L)
| Chiusura precedente | 2,8900 |
| Aperto | 0,0000 |
| Denaro | 0,0000 x N/D |
| Lettera | 0,0000 x N/D |
| Min-Max giorno | 0,0000 - 0,0000 |
| Intervallo di 52 settimane | |
| Volume | |
| Media Volume | 401 |
| Capitalizzazione | N/D |
| Beta (5 anni mensile) | 1,07 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,3940 |
| Prossima data utili | 07 mag 2024 - 13 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireLisata Therapeutics Announces Participation in Upcoming Conferences in October
BASKING RIDGE, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, PhD, President and Chief Executive Officer of Lisata, will present at two upcoming conferences in October. Details of the events are as follows: BioCentury-BayHelix East-West Biopharma Summit Oc
- GlobeNewswire
Lisata Therapeutics Announces Participation in InfoSec World 2023
Gregory Berkin, Chief Information Officer of Lisata, to participate in keynote discussion on CISO leadership and managing the risks of artificial intelligenceBASKING RIDGE, N.J., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, announces that Gregory Berkin, Chief Information Officer at Lisata, will
- GlobeNewswire
Lisata Therapeutics Announces First Patient Treated in the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Advanced Solid Tumors
Phase 2a double-blind, placebo-controlled, multi-center, randomized study evaluating LSTA1 in combination with standards of care versus standards of care alone in subjects with advanced solid tumors including cholangiocarcinoma, head and neck squamous cell carcinoma, or esophageal squamous cell carcinoma First patient treated in the head and neck squamous cell carcinoma cohort BASKING RIDGE, N.J., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Compa
